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BACKGROUND: The mechanisms underlying the dedifferentiation and 
lineage conversion of adult human fibroblasts into functional endothelial 
cells have not yet been fully defined. Furthermore, it is not known whether 
fibroblast dedifferentiation recapitulates the generation of multipotent 
progenitors during embryonic development, which give rise to endothelial 
and hematopoietic cell lineages. Here we established the role of the 
developmental transcription factor SOX17 in regulating the bilineage 
conversion of fibroblasts by the generation of intermediate progenitors.
METHODS: CD34+ progenitors were generated after the dedifferentiation 
of human adult dermal fibroblasts by overexpression of pluripotency 
transcription factors. Sorted CD34+ cells were transdifferentiated into 
induced endothelial cells and induced erythroblasts using lineage-specific 
growth factors. The therapeutic potential of the generated cells was 
assessed in an experimental model of myocardial infarction.
RESULTS: Induced endothelial cells expressed specific endothelial cell 
surface markers and also exhibited the capacity for cell proliferation and 
neovascularization. Induced erythroblasts expressed erythroid surface 
markers and formed erythroid colonies. Endothelial lineage conversion 
was dependent on the upregulation of the developmental transcription 
factor SOX17, whereas suppression of SOX17 instead directed the cells 
toward an erythroid fate. Implantation of these human bipotential CD34+ 
progenitors into nonobese diabetic/severe combined immunodeficiency 
(NOD-SCID) mice resulted in the formation of microvessels derived 
from human fibroblasts perfused with mouse and human erythrocytes. 
Endothelial cells generated from human fibroblasts also showed 
upregulation of telomerase. Cell implantation markedly improved vascularity 
and cardiac function after myocardial infarction without any evidence of 
teratoma formation.
CONCLUSIONS: Dedifferentiation of fibroblasts to intermediate CD34+ 
progenitors gives rise to endothelial cells and erythroblasts in a SOX17-
dependent manner. These findings identify the intermediate CD34+ 
progenitor state as a critical bifurcation point, which can be tuned to 
generate functional blood vessels or erythrocytes and salvage ischemic 
tissue.
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Direct conversion of somatic cells such as fibro-blasts into other cell types for organ and tissue re-generation holds great therapeutic promise.1 Stud-
ies have shown that fibroblasts can be reprogrammed 
into hepatocyte-like cells, cardiomyocytes, neurons, en-
dothelial cells (ECs), and erythroid progenitors.2–6 Direct 
conversion of fibroblasts to regenerative therapeutic 
cells is thus not only more expedient than the intermedi-
ate generation of iPSCs, which requires further differen-
tiation into specific lineage cells, but also avoids risk of 
teratoma formation caused by any residual pluripotent 
cells.7 Two general strategies are used to convert fibro-
blasts into ECs. One relies on dedifferentiation, in which 
the pluripotency-inducing transcription factors OCT-4, 
KLF4, SOX2, and c-MYC are expressed to partially dedif-
ferentiate fibroblasts, and this is followed by applying 
endothelial growth factors such as vascular endothelial 
growth factor to induce terminal EC differentiation.8–10 
The second approach relies on the targeted overexpres-
sion of developmental transcription factors, such as 
ETV2, known to regulate formation of ECs.11,12
However, little is known about the underlying mecha-
nisms that enable reprogramming and whether these 2 
strategies—partial dedifferentiation and directed vascular 
transcription factor overexpression—can be combined 
to induce more efficient EC generation. The advantage 
of the dedifferentiation strategy is that it may generate 
multipotent progenitors that can in turn be directed into 
multiple regenerative cell lineages. ECs generated during 
embryonic development are derived from mesodermal 
progenitors and hemangioblasts, which are a short-lived 
cell population that generates both endothelial and he-
matopoietic lineage cells.13–15 Thus, we surmised that if 
dedifferentiation of adult fibroblasts recapitulates embry-
onic development, then generation of fibroblast-derived 
progenitors may also provide a means of forming new 
blood vessels along with hematopoietic cells, including 
erythrocytes. Human hemangioblasts reportedly have dis-
tinct subpopulations expressing different surface markers 
such as CD34.16–18 Here, we demonstrated that dedif-
ferentiation of human fibroblasts generated bipotential 
CD34+ progenitors capable of differentiating into ECs and 
erythroblasts. The transcription factor SOX17 functioned 
as a tunable rheostat-like switch in CD34+ cells, giving 
rise to ECs and the erythroid lineage. Further, we demon-
strated that implantation of CD34+ progenitors generated 
functional human blood vessels and improved cardiac 
function in infarcted mouse hearts.
METHODS
Cell Culture and Transfection
Normal human adult dermal fibroblast cells (Lonza, CC-2511) 
and human neonatal dermal fibroblast cells (Lonza, CC-2509) 
were cultured in DMEM (Life Technologies, 21063) containing 
10% FBS, 50 U/mL penicillin and 50 mg/mL streptomycin, 
2.25 mM L-glutamine, and 2.25 mM nonessential amino acids. 
Fibroblasts (5.0×105/100 mm dish) and PLAT-A cells (Cell 
Biolabs Inc. RV-102) (5.0×106/100 mm dish) were plated in 
DMEM medium without antibiotics; 100 mm dishes were plated 
with PLAT-A cells, 1 dish per plasmid, each encoding OCT4, 
KLF4, SOX2, and c-MYC (OKSM; all obtained from Addgene and 
were gifts from Shinya Yamanaka: pMXs-hOCT3/4, Addgene 
plasmid #17217; pMXs-hSOX2, Addgene plasmid #17218; 
pMXs-hKLF4, Addgene plasmid #117219; pMXs-hc-MYC, 
Addgene plasmid #17220), as well as green fluorescent protein 
(GFP) as a control. On day 0, Fugene HD transfection reagent 
(Roche, E2311) and 10 μg of the appropriate plasmid DNA 
were added to one 100 mm dish cultured with PLAT-A cells. The 
virus-containing medium was collected and filtered from dishes 
of transfected PLAT-A cells on days 1 and 2 for titration. The 
medium of human fibroblasts was replaced with virus-containing 
medium on days 1 and 2. On day 3, the medium was switched to 
DMEM/F12 (Life Technologies, 11330), 20% KnockOut serum 
replacement (Life Technologies, 10828), 10 ng ml−1 bFGF (R&D 
Systems, 233-FB), 1 mM GlutaMAX, 0.1 mM nonessential amino 
acids, and 55 μM β-mercaptoethanol with medium changes 
Clinical Perspective
What Is New?
• Adult human skin fibroblasts can be dedifferentiated 
to intermediate CD34+ progenitors, which in turn 
give rise to endothelial cells and erythrocytes.
• Lineage conversion of fibroblasts by partial dedif-
ferentiation recapitulates in part the embryonic 
development of the vasculature as evidenced by 
upregulation of the anti-aging enzyme telomer-
ase and the bilineage potential of the generated 
progenitors.
• The transcription factor SOX17 functions as a switch 
that regulates cell fate of CD34+ progenitors toward 
an endothelial versus erythroid lineage.
• Implanted fibroblast-derived CD34+ progenitors sta-
bly engraft to form functional human blood vessels 
in mice that improve cardiac function after myocar-
dial infarction.
What Are the Clinical Implications?
• Dedifferentiation of fibroblasts to multipotent pro-
genitors can generate patient-specific functional 
endothelial cells.
• When human fibroblast-derived progenitors are 
implanted in a mouse model of myocardial infarc-
tion, they are able to improve cardiac function.
• The molecular switch SOX17 provides a means to 
optimize the generation of endothelial cells for vas-
cular tissue regeneration or disease modeling.
• The upregulation of telomerase suggests that fibro-
blast dedifferentiation may avoid premature aging 
of the cells during the lineage conversion process, 
which could be especially helpful when deriving per-
sonalized endothelial cells from skin fibroblasts of 
older patients.
SOX17 Regulation of Lineage Conversion
ORIGINAL RESEARCH 
ARTICLE
Circulation. 2017;135:2505–2523. DOI: 10.1161/CIRCULATIONAHA.116.025722 June 20/27, 2017 2507
17.6%11.4%
0.2%
0.2% 0.3% 0.2%
Fib Adult De-Diff Fib Neonatal De-Diff Fib
Is
ot
yp
e
C
D
34
A
B D
E
F
Isotype
TRA180
PE Log
Isotype
TRA180
PE Log
PE Log
Isotype
TRA160
Isotype
TRA160
PE Log
CD34+ Progenitors iPSCsG
C
H I
Fib Adult 
De-Diff-Fib
Neonatal
De-Diff-Fib
Figure 1. Generating CD34+progenitors from human dermal fibroblasts.  
A, Schematic of converting human dermal fibroblasts into induced endothelial cells (iECs) and induced Erythroblasts (iErythro-
blasts) by sorted CD34+ progenitors from dedifferentiated fibroblasts (De-Diff-Fib) at day 7. B through D, Quantitative polymerase 
chain reaction (PCR) analysis of the mesodermal marker CD34 (B), pluripotency markers OCT4 (C), and Nanog (D) during adult fi-
broblast dedifferentiation from days 0 to 7 (n=4). E, Representative flow-cytometry plots of the mesodermal marker (Continued )  
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every day for 5 days to continue the dedifferentiation phase. The 
fibroblasts transduced by OKSM and maintained in this medium 
were referred to as dedifferentiated fibroblasts. The protocol is 
shown in Figure 1A. All cell lines were maintained in an incubator 
(37°C, 5% CO2).
Isolation of CD34+ Progenitors From Dedifferentiated 
Fibroblasts
We identified the CD34+ progenitors by CD34, a marker of 
human progenitors, including endothelial and hematopoietic 
progenitors.18 We isolated CD34+ cells generated during dedif-
ferentiation of fibroblast with anti-CD34–conjugated magnetic 
beads (Miltenyi, 130-046) according to manufacturer’s instruc-
tions with slight modifications. Briefly, ≤109 cells were incu-
bated at 4°C with 100 μl of Fc-blocking solution and 100 μl 
anti-CD34 magnetic beads in a total volume of 500 μl FACS 
blocking buffer. After 30 minutes, cells were sorted by 2 con-
secutive rounds of column separation through applying mag-
netic activated cell sorting (MACS, Miltenyi Biotec) separation 
magnets to increase purity.
Differentiation of CD34+ Progenitors Into Induced ECs 
(iECs)
Isolated CD34+ progenitors were plated in 0.1% gelatin–coated 
plates (2×105/6 well), cultured in endothelial medium EGM-2 
(CC-4176), and supplemented with 50 ng/mL BMP4 (R&D 
Systems, 314-BP) and 50 ng/mL vascular endothelial growth 
factor (R&D Systems, 293-VE) to induce endothelial lineage 
specification, and the medium was changed every other day. 
On reaching ≈90% confluence, cells were split 1:3. Primary 
human aortic ECs were purchased from Lonza (CC-2535) and 
cultured in EGM-2 medium as control cells.
Differentiation of CD34+ Progenitors Into Induced 
Erythroblasts (iErythroblasts)
To generate erythroid cells, sorted CD34+ progenitors were 
plated in 0.1% gelatin-coated plates (1.0×106/well in a 6-well 
plate) and cultured for 4 days in erythroblast induction medium, 
which consisted of 49% IMDM (Life Technologies, 12440), 
49% Ham’s F12 (Life Technologies, 11765), 1% ITSX, 1% 
lipid (Life Technologies, 11905-031), 5 mg/100 mL I-ascorbic 
acid (Sigma, A8960), 500 mg/100 mL BSA (Sigma, A7030), 
and 200uM 1-thioglycerol (Sigma, M6145), supplemented 
with 100 ng/mL SCF (PeproTech, 300–07), 10 ng/mL inter-
leukin-3 (PeproTech, 200–03), 5 U/mL EPO (R&D Systems, 
287-TC), 40 ng/mL insulin-like growth factor-1(Sigma I-3769), 
1 μM Dexamethsone (Sigma, D2915), and 50 ng/mL Flt3-L 
(PeproTech, 300–19) (Figure 1A). Unlike adherent ECs, induced 
erythroblasts detached on generation and were collected as 
nonadherent cell fraction at day 4 for characterization.
Matrigel Plug In Vivo Angiogenesis Assay
To test the ability of iECs to form blood vessels in vivo, we 
performed an in vivo gel plug assay.19 Nonobese diabetic/
severe combined immunodeficiency (NOD-SCID) mice were 
used to avoid the rejection of human cells. Anesthesia 
was induced using a mixture of xylazine (10 mg/kg) and 
ketamine (100 mg/kg) in saline IP. A total of 1×106 cells 
(either CD34+ progenitors, fibroblasts, or aortic ECs) were 
suspended in 200 μl of cold growth factor-reduced Matrigel 
Matrix (Corning, 356234). We then injected the cell-con-
taining Matrigel solutions subcutaneously in the abdomen. 
The mice were euthanized after 1 week implantation, and 
the Matrigel plugs were removed by a wide excision of the 
skin, fixed in 10% formalin overnight, embedded in paraffin, 
and sectioned. Five sections from each plug were randomly 
selected to quantify human vessels. Quantification of vessel 
density in angiogenesis plugs was shown per section per 
plug. Each mouse was injected with 3 plugs containing iECs, 
fibroblasts, or mature ECs. Each data point represents 1 
plug from 1 mouse.
Myocardial Infarction (MI) Surgery and Intramyocardial 
Injection of Cells
The MI surgery is described in detail in the online-only Data 
Supplement. For the cell implantation, 40 μl of concentrated 
cells ‒1×106 CD34+ progenitors or fibroblasts suspended in 
growth factor-reduced Matrigel (Matrigel basement-membrane 
matrix from BD) were injected into the border zone of the 
infarct at 2 to 3 different areas using a Gastight 1710 syringe 
(Hamilton) immediately after ligation. The injected cells had 
been prelabeled with lentiviral GFP. The surgeon was blinded 
to the nature of the injected cells. Two weeks later, hearts 
were retrograde perfused with 4% paraformaldehyde by the 
aorta, fixed in 4% paraformaldehyde for 4 hours, incubated 
in 30% sucrose overnight, embedded in OCT, frozen, and 
cryosectioned. Ten sections with injected GFP cells from each 
heart were used for quantification of human CD31+ vessels. 
Quantification of vessel density was shown as vessels per sec-
tion per heart.
Experimental Animals
Immune deficient NOD-SCID mice were purchased from 
Jackson Laboratory (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, strain 
005557). All animal experiments were conducted in accor-
dance with National Institutes of Health guidelines for the care 
and use of live animals and were approved by the Institutional 
Animal Care and Use Committee  of the University of Illinois.
Statistics
Cell culture studies on fibroblasts and endothelial cells were 
performed with commercially obtained primary cells from mul-
tiple batches (Lonza) and are biological replicates. Values were 
reported as mean±SE. The statistical analysis was performed 
with GraphPad Prism and is indicated in the figure legends. 
Bonferroni corrections were used for analysis of variance 
with multiple comparisons. Statistical significance was set at 
P<0.05.
Figure 1 Continued. CD34+ in fibroblasts, adult De-Diff-Fib, and neonatal De-Diff-Fib. F, Quantification and statistical analysis 
of CD34+ cells in fibroblasts (n=3), adult De-Diff-Fib (n=6), and neonatal De-Diff-Fib (n=6) from flow cytometry. G through I, 
Representative flow-cytometry overlay plots of the pluripotency markers: human TRA-160 and TRA-180 in CD34+ progenitors (G) 
and iPSCs (H) and quantification of TRA-160 or TRA-180-positive cells (I) in CD34+ progenitors and iPSCs. Data are presented 
as mean±SE, *P<0.05, **P<0.01, ***P<0.001, compared with day 0 in B, C, and D, compared with fibroblasts in F, using 
repeated measures 1-way analysis of variance in B, C, and D and using 1-way analysis in F. N.D. indicates not detected in I.
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Figure 2. Induction of endothelial cells. 
 A, Quantitative polymerase chain reaction (PCR) analysis of endothelial-specific genes VE-cadherin, CD31, VWF, and FLK1 in 
induced endothelial cells (iECs) from days 0 to 10, normalized to day 0 (n=3). B, Representative flow-cytometry plots of endothe-
lial markers VE-cadherin and CD31 at day 10 in human aortic ECs and iECs. C, Quantification of VE-cadherin+ and CD31+ cells 
in iECs at day 10 from flow cytometry (n=4). D, Immunoblots of the endothelial-specific proteins human VE-cadherin, CD31, and 
FLK1 in iECs and fibroblasts; β-Actin served as a control. E, Representative micrographs of immunocytochemistry (Continued)  
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RESULTS
Dedifferentiation of Human Fibroblasts Into 
CD34+ Progenitors
CD34+ progenitors were generated by expressing 
the Yamanaka factors OCT4, KLF4, SOX2, and c-MYC 
(OKSM) in human fibroblasts, followed by 7 days of de-
differentiation (Figure 1A). These fibroblast-derived cells 
were referred to as dedifferentiated fibroblasts, and we 
subsequently applied endothelial or erythroid lineage 
growth factors to differentiate them into ECs or erythro-
blasts (Figure 1A and Figure I in the online-only Data Sup-
plement). As shown in Figure 1B, expression of CD34 
gradually increased during the dedifferentiation period 
and reached a plateau at days 6 to 7. OCT4 mRNA levels 
peaked at days 3 to 4 and then steadily decreased (Fig-
ure 1C), indicating that pluripotency was circumvented. 
Expression of SOX2, c-MYC, and KLF4 exhibited similar 
expression changes as OCT4. We also assessed the ex-
pression of NANOG, an endogenous pluripotency factor, 
which was not part of the OKSM cocktail. NANOG was 
downregulated during fibroblast dedifferentiation (Fig-
ure 1D), confirming that short-term induction of 7 days 
did not induce pluripotency. We used day 7 cells for sub-
sequent studies because CD34 expression had reached 
a plateau, and there was no evidence of pluripotency at 
this stage. Assessing generation of CD34+ cells by flow 
cytometry, we found that dedifferentiation of both human 
neonatal and adult dermal fibroblasts gave rise to CD34+ 
cells, with higher CD34+ yield from neonatal compared 
with adult fibroblasts (16.3±2% versus 8.7±1%; Fig-
ure 1E and 1F). We then focused on human adult dermal 
fibroblasts because of their potential utility for vascular 
regeneration in patients.
The CD34+ cells were also evaluated for their clonal 
expansion potential and the pluripotency surface mark-
ers TRA-160 and TRA-180, endothelial surface markers 
VE-cadherin and CD31, and the erythroblast/erythrocyte 
surface marker CD235a by flow cytometry. Plating of 
individual CD34+ cells did not result in any formation of 
colonies. We also found that CD34+ cells did not express 
markers of pluripotency (Figure 1G through 1I), endo-
thelial differentiation (Figure IIA and IIB in the online-only 
Data Supplement), or erythroblast differentiation (Figure 
IIC and IID in the online-only Data Supplement), demon-
strating that the cells were undifferentiated progenitors.
Conversion of Fibroblast-Derived CD34+ 
Progenitors Into ECs
We isolated CD34+ progenitors from the dedifferentiated 
fibroblast population using magnetic bead sorting and 
exposed the cells to an EC lineage induction medium 
consisting of standard endothelial growth medium sup-
plemented with the EC differentiation factors vascular 
endothelial growth factor and BMP-4 for 10 days. Dur-
ing the induction phase, gene expression of EC mark-
ers VE-cadherin, VWF, CD31, and FLK1 progressively 
increased (Figure 2A). The induction of CD34+ cells was 
terminated on day 10 when EC marker levels plateaued 
(data not shown). Flow cytometry of cells at day 10 dem-
onstrated that 7.8±3% of cells were positive for VE-cad-
herin, 8.4±3% of cells for CD31, and 4.9±1% of cells 
for both surface markers (Figure 2B and 2C). We found 
92.9±1.2% of VE-cadherin+ iECs continued to express 
CD34 after endothelial differentiation (Figure IIE in the on-
line-only Data Supplement). Western blotting established 
upregulation of VE-cadherin, CD31, and FLK1 in these 
generated cells, which we termed iECs (Figure 2D). Im-
munocytochemistry staining demonstrated that the bulk 
of VE-cadherin was localized in the cytoplasm in these 
nonconfluent iECs as opposed to the cell surface mem-
brane where VE-cadherin is typically found in confluent 
adherent ECs (Figure 2E). The relatively high-cytosolic 
VE-cadherin expression also explained why only 8% of 
iECs were positive for VE-cadherin by flow cytometry as 
it monitors the cell surface expressed protein. Because 
VE-cadherin transinteractions between cells stabilize VE-
cadherin at the cell membrane and promote formation of 
adherens junctions,20 we next cocultured the iECs with 
primary adult human aortic ECs. Confocal imaging dem-
onstrated that this increased the membrane localization 
of VE-cadherin such that iECs formed characteristic ad-
herens junctions by homotypic interactions (Figure 2F). 
We also examined the gene expression levels of the en-
dothelial markers VE-cadherin, CD31, FLK1, and VWF in 
CD31+ bead-sorted iECs at day 10 of induction. The iEC 
mRNA levels of these endothelial markers were ≈50% of 
those in mature human ECs but 100- to 1000-fold higher 
than those in fibroblasts and CD34+ progenitors (Figure 
IIIA through IIID in the online-only Data Supplement).
We next performed a transcriptomic analysis of adult 
fibroblasts, fibroblast-derived CD34+ progenitors, iECs, 
and primary human ECs. A heat map of global gene ex-
Figure 2 Continued. staining of human VE-cadherin (green) and human CD31 (red) of iECs at day 10; nuclei were stained by 
DAPI. Scale bars: 50 µm. F, Confocal micrographs of immunofluorescence staining of human VE-cadherin (red) in iECs (labeled 
by CellTracker Green, Invitrogen Catalog #: C7025TM) co-cultured with ECs (labeled by CellTracker Orange, Invitrogen Catalog 
#: C2927) for 2 days. Scale bars: 20 µm. G‒I, Analysis of cDNA microarrays in adult fibroblasts, CD34+ progenitors (labeled as 
CD34+), iECs, and ECs heat map of global gene using hierarchical clustering analysis (G), heat map of endothelial genes (H), and 
fibroblast genes (I). The color bars indicate gene expression level in log2 scale. Blue to red color represents low to high expres-
sion level. Data are presented as mean±SE; *P<0.05, **P<0.01, ***P<0.001, compared with day 0. #P<0.05, ##P<0.01, 
###P<0.001, compared with day 3; &P<0.05, &&&P<0.05 compared with day 7 using repeated measures 1-way analysis in A.
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Figure 3. Characterization of induced endothelial cells (iECs).  
A and B, The permeability of iECs in response to thrombin. Transendothelial electric resistance (TER) was measured for 90 min-
utes in fibroblasts and iECs. Thrombin (3.5µg/mL, 0.5 U) was added as indicated. The time course of resistance in fibroblasts 
and iECs normalized to baseline (A) and statistical analysis (B) of percentage of deduction of resistance in response to thrombin 
in fibroblasts and iECs (n=4). C and D, In vitro capillary network formation of iECs and fibroblasts on Matrigel. The (Continued ) 
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pression revealed that iECs clustered with ECs, whereas 
CD34+ progenitors clustered with fibroblasts (Figure 2G). 
Thus, iECs exhibited a gene expression profile similar to 
adult primary ECs, whereas fibroblast-derived CD34+ pro-
genitors retained fibroblast signatures. Heat maps of EC- 
and fibroblast-specific genes indicated that gain of EC 
identify and loss of fibroblast signatures occurred during 
the transition from CD34+ cells to iECs (Figure 2H and 2I).
Fibroblast-Derived iECs Are Functional ECs
Key functions of ECs are to form a restrictive and dynamic 
barrier and upregulate cell surface adhesion molecules in 
response to inflammatory stimuli. Thus, we assessed tran-
sendothelial electric resistance in a confluent monolayer 
of iECs as a measure of the barrier function. In response 
to thrombin, we observed a significant decrease in tran-
sendothelial electric resistance of iECs, while monolayers 
of parent fibroblasts showed no such response (Figure 
3A and 3B and Figure IV in the online-only Data Supple-
ment). It is important to note that iECs exhibited resto-
ration of the barrier, a physiological adaptive response 
seen in native endothelium. We also demonstrated that 
iECs formed capillary networks in 2D-Matrigel (Figure 3C 
and 3D), whereas fibroblasts predominately remained as 
single cells or cell clusters. To evaluate responses to the 
proinflammatory cytokine tumor necrosis factor-α , we 
assessed expression of adhesion molecules VCAM1 and 
E-Selectin. iECs responded with upregulation of VCAM1 
and E-selectin proteins (Figure 3E) and mRNA (Figure 3F) 
in the same manner as primary human ECs.
Proliferation Potential and Telomerase 
Expression in iECs
Because ECs’ ability to proliferate is required for vascu-
lar regeneration, we assessed proliferative potential of 
iECs. As shown in Figure 3G and 3H, 20% to 30% of iECs 
were labeled with BrdU, a value similar to the prolifera-
tion rate of primary human ECs. Cell expansion induces 
cell senescence and results in cell cycle arrest because 
of continuous shortening of telomeres.21–23 Therefore, 
we assessed whether the generated iECs represented 
an aging cell population. We determined telomerase ac-
tivity because it maintains telomere length and protects 
against premature senescence in embryonic and neo-
natal cells.21–23 We observed that telomerase activity of 
iECs, as assessed by a telomeric repeat amplification 
protocol, was significantly greater compared with adult 
fibroblasts or primary adult human ECs (Figure 3I and 
3J). However, despite higher telomerase activity, iECs 
did not show significantly elevated expression of the plu-
ripotency transcription factor OCT4 or the pro- to onco-
gene c-MYC compared with fibroblasts (Figure VA and VB 
in the online-only Data Supplement).
Fibroblasts Also Give Rise to Erythroblasts by 
Intermediate CD34+ Progenitors
Fibroblast-derived CD34+ progenitors were cultured in 
erythroblast induction medium for 4 days to assess the 
generation of erythroblasts. Unlike iECs, which remained 
adherent to the substrate, emerging erythroblasts de-
tached from the CD34+ cell layer. Hema 3-staining cyto-
spin preparations of iErythroblasts showed morphology 
reflecting different stages of maturation from basophilic 
erythroblasts to polychromatic erythroblasts (Figure 4A). 
To address whether iErythroblasts expressed an ery-
throid marker, we stained the cytospin preparations for 
the erythroid marker glycophorin CD235a. We found that 
7.1±1% of nucleated were CD235a+ (Figure 4B and 4C). 
Flow cytometry demonstrated that 4.2%±0.8% of cells 
undergoing erythroblast induction were CD235a+ (Fig-
ure 4D and 4E). Gene expression analysis by quantitative 
polymerase chain reaction showed expression of human 
hemoglobin beta and hemoglobin gamma, confirming the 
erythroid nature of the generated human cells (Figure 4F). 
The expression levels of hematopoietic transcriptional fac-
tors –RUNX1 and PU.1, as well as the erythroblast tran-
scription factor GATA1,24,25 were also markedly enhanced 
when compared with fibroblasts (Figure 4G). Moreover, 
erythroid colony-forming-cell assay demonstrated forma-
tion of distinct erythroid colonies (Figure 4H and 4I).
SOX17 Mediates Generation of iECs From CD34+ 
Progenitors
We next evaluated expression of vascular developmen-
tal genes during iEC induction as shown in a quantita-
Figure 3 Continued. representative images (C) and statistical analysis (D) of tube network formation in fibroblasts, iECs, and 
ECs (n=3). E and F, The inflammation response of iECs. FACS analysis (E) and quantitative realtime-polymerase chain reaction 
(PCR) measurement (F) for CD106 and CD62E on tumor necrosis factor-α (TNF-α) activated ECs and iECs (n=3). G and H, The 
proliferation of iECs. Representative flow-cytometry plots (G) of the proliferation capacity of iECs and ECs as assessed by BrdU 
uptake and statistical analysis (H) of the percentage of BrdU+ cells in iECs and ECs (n=3). I and J, The telomerase activity of 
iECs. Telomerase activity was measured by a telomeric repeat amplification protocol (TRAP) assay. PCR amplification results of 
TRAP (I) from positive control, negative control, fibroblasts, ECs, and iECs; and statistical analysis (J) of telomerase activity in 
above cell types (n=3). Data are presented as mean±SE; *P<0.05, **P<0.01, ***P<0.001, N.S. P>0.05; compared with fibro-
blasts in B, D through F, and J; compared with ECs in E, F, and H using Student t test in B and H, 1-way analysis of variance in J 
and 2-way analysis in E and F.
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Figure 4. Induction and characterization of induced Erythroblasts (iErythroblasts). 
A, Representative Hema 3 staining images of iErythroblasts. Scale bars: 20 µm. B and C, Immunocytochemistry analysis of 
erythrocyte markers CD235a in iErythroblasts: representative immunofluorescence images of iErythroblasts (B) and statistical 
analysis (C) of percentage of CD235a+ cells in fibroblasts and iErythroblasts (n=4). Scale bars: 20 µm. D and E, FACS analysis 
of erythrocyte markers CD235a. Representative flow-cytometry plots (D) and statistical analysis (E) of percentage (Continued )  
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tive real-time polymerase chain reaction  heat map (Fig-
ure 5A). We observed that the transcriptional regulator 
SOX17 (a member of Sry-transcription factor family) was 
significantly upregulated during iECs induction. The tran-
scription factor ETV2 (also known as ER71), which when 
overexpressed induced fibroblast-to-endothelial transi-
tion,11,12 was not significantly upregulated during lineage 
conversion of CD34+ progenitors to iECs.
SOX17, a member of the Sry-related high-mobility 
group domain family F (SoxF) transcriptional factors, 
is a key regulator of EC and hematopoietic develop-
ment during embryogenesis. Thus, we next investigated 
whether the transcription factor SOX17 identified ear-
lier was required for conversion of CD34+ progenitors 
to iECs. SOX17 progressively increased during the 10-
day induction period (Figure 5B). Immunoblotting con-
firmed upregulation of SOX17 in iECs compared with 
fibroblasts (Figure 5C). To assess whether expression 
of SOX17 was required for induction of iECs, lentiviral 
shRNAs were used to deplete SOX17 during EC induc-
tion phase. CD34+ progenitors were infected with len-
tiviruses encoding SOX17 shRNA or scramble shRNA 
on day 1 with 95% transduction efficiency (Figure VIA 
through VIC in the online-only Data Supplement). Using 
multiple shRNA constructs, we identified a SOX17-shR-
NA, which achieved >90% SOX17 depletion (Figure VID 
in the online-only Data Supplement). Depletion of SOX17 
prevented the differentiation of CD34+ progenitors to 
iECs as demonstrated by suppression of the EC-specific 
markers (VE-cadherin, CD31, and FLK1) at both mRNA 
and protein levels when compared with scrambled shR-
NA (Figure 5D through 5F).
Based on these findings, we next determined 
whether overexpression of SOX17 would enhance EC 
lineage conversion. CD34+ progenitors undergoing 
conversion were transduced with retroviruses encod-
ing SOX17-GFP or GFP on day 1. We observed signifi-
cant increases in mRNA and protein levels of VE-cad-
herin, CD31, and FLK1 when compared with controls 
(Figure 5G through 5I). Quantitative analysis with flow 
cytometry showed that overexpression of SOX17 en-
hanced EC differentiation ≈9-fold as evidenced by in-
creased fraction of VE-cadherin‒positive cells when 
compared with using only growth factors for EC con-
version (50.9±3% versus 6.1±2%) (Figure 5J and 5K). 
Thus, conversion of CD34+ progenitors into iECs was 
markedly enhanced by activation of the transcription 
factor SOX17.
SOX17 Inhibits Generation of iErythroblasts From 
CD34+ Progenitors
We next examined whether SOX17 also regulates tran-
sition of CD34+ progenitors, the point of bifurcation, 
into iErythroblasts. Here we found that the expression 
of SOX17 increased in CD34+ progenitors when com-
pared with the parent fibroblasts but progressively 
decreased during the induction of iErythroblasts (Fig-
ure 6A), consistent with the role of SOX17 in favoring 
EC fate conversion at the CD34+ progenitor bifurca-
tion state described earlier. To explore the role of 
SOX17 in iErythroblast generation, SOX17 was deplet-
ed using shRNA in fibroblasts before dedifferentiation. 
Depletion of SOX17 increased the expression of the 
hematopoietic transcription factors RUNX1 and PU.1 
as well as erythropoiesis-specific regulator GATA1 
during erythroblast induction (Figure 6B). Flow cytom-
etry confirmed increased erythropoiesis on SOX17 
depletion trending toward increased erythropoiesis 
(Figure 6C and 6D). In addition, we observed that de-
pleting SOX17 significantly increased the formation of 
erythroid colonies (Figure 6E and 6F), consistent with 
the role of SOX17 in directing the fate of CD34+ pro-
genitors to either iECs or erythroblasts; that is, the 
presence of SOX17 favored the iEC lineage, whereas 
its downregulation enhanced erythroid specification, 
indicative of the rheostat function of SOX17 at the 
CD34 bifurcation point.
CD34+ Progenitors Form Blood Vessels and 
Erythrocytes In Vivo and Restore Myocardial 
Function in Mice
We next assessed the in vivo significance of human fi-
broblast-derived CD34+ progenitors in giving rise to iECs 
and iErythroblasts. We injected growth factor-reduced 
Matrigel containing CD34+ progenitors, fibroblasts, or 
primary human ECs subcutaneously into immune defi-
cient NOD-SCID mice. Matrigel plugs explanted after 1 
week showed that implantation of either primary aortic 
human ECs (controls) or CD34+ progenitors induced for-
mation of blood vessels, whereas blood vessels did not 
form after implantation of fibroblasts alone (Figure 7A 
through 7C)
To evaluate whether the ECs lining the newly 
formed blood vessels and erythrocytes in the Matrigel 
plug were derived from the implanted human CD34+ 
Figure 4 Continued. of CD235a+ cells in iErythroblasts and fibroblasts (n=6). F, Quantitative polymerase chain reaction (PCR) 
analysis of hemoglobin β and hemoglobin γ by Taqman assay in the fibroblasts and iErythroblasts (n=3). G, Quantitative PCR 
analysis of transcriptional factors of hematopoietic cells GATA1, RUNX1, and PU.1 in fibroblasts and iErythroblasts (n=4). H and 
I, Erythroid colony-forming cell (CFC) assays. Representative erythroid colony images (H) and statistical analysis (I) of erythroid 
colony numbers of fibroblasts and iErythroblasts (n=3). Data are presented as mean±SE; *P<0.05, **P<0.01, ***P<0.001, 
compared with fibroblasts using the Student t test in C, E, and I and the Student t test with multiple comparisons (Bonferroni 
correction) in F and G.
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Figure 5. SOX17 is required for the induction of induced endothelial cells (iECs) from CD34+ progenitors.  
A, Heat map of endothelial developmental genes during iEC induction (iECs at days 0, 3, 7, and 10) by quantitative real-time poly-
merase chain reaction (PCR). The color key indicates gene expression level relative to B2M (beta-2-microglobulin) normalized to iECs at 
day 0. Blue to red color represents low to high expression level. B and C, The expression level of SOX17 in iECs. The time (Continued ) 
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progenitors or host mouse vasculature, we used a 
human-specific CD31 antibody to stain human ves-
sels. We also used a human-specific CD235a antibody 
and a mouse-specific TER119 antibody to stain human 
and mouse erythrocytes, respectively, after confirm-
ing the human species specificity (Figure VII in the 
online-only Data Supplement). Staining of explanted 
Matrigel plugs containing CD34+ progenitors demon-
strated that vessels were positive for human CD31 
and had greater angiogenesis than those implanted 
with mature ECs (Figure 7B and 7C). We further found 
that a small fraction of erythrocytes within the ves-
sels stained positive for human CD235a (Figure 7D). 
We observed that the newly formed human blood ves-
sels predominantly contained murine erythrocytes, 
indicating communication between the host mouse 
vasculature and newly formed vessels derived from 
human CD34+ progenitors. It is important to note that 
Matrigel plugs containing primary human ECs showed 
presence of erythrocytes derived only from host mice 
(Figure VIIIA and VIIIB in the online-only Data Supple-
ment).
To further demonstrate the functionality of formed 
human vessels, fluorescence-labeled lectins that stain 
species-specific endothelium were injected intrave-
nously before harvesting Matrigel implants contain-
ing GFP-labeled CD34+ progenitors or GFP-labeled 
fibroblasts. We used Rhodamine-labeled UEA I to 
assess functional human endothelium and DyLight 
649-labeled GS-IB4 for mouse endothelium.26 Colo-
calization of GFP and UEA I+ demonstrated the func-
tionality of CD34+ progenitor-derived human vessels 
(Figure 7E), whereas areas without GFP+/UEA I+ cells 
predominantly consisted of GS-IB4+ host mouse ves-
sels (Figure 7E). It is important to note that we identi-
fied selected areas of close proximity between human 
CD34+ progenitor cells and mouse host GS-IB4+ ves-
sels (Figure 7F and Movie I in the online-only Data Sup-
plement), which likely represented communications 
between the host vasculature and neovessels from 
the implanted cells, thus explaining why systemic in-
travenous injection of a human-specific lectin into the 
mice was able to stain the CD34+ progenitor-derived 
human vessels. No UEA I+ human vessels were de-
tected in plugs implanted with fibroblasts (Figure 7G). 
We also found examples of GFP+ erythrocytes (Figure 
IX in the online-only Data Supplement), further confirm-
ing the capacity of CD34+ progenitors to mature into 
erythrocytes in vivo.
To assess the teratoma-forming capacity of CD34+ 
progenitors, immune deficient NOD-SCID mice were 
implanted with CD34+ progenitors or iPSCs (positive 
control) and observed for 8 weeks. We found that the 
implantation of iPSCs for 8 weeks formed teratomas, 
whereas the CD34+ progenitors did not form any ter-
atomas, thus underscoring their safety and lack of 
pluripotency (Figure XA through XD in the online-only 
Data Supplement).
We next used a mouse MI model to assess whether 
CD34+ progenitors enhance perfusion and cardiac 
function. We injected a Matrigel suspension contain-
ing either CD34+ progenitors or control fibroblasts 
in the peri-infarct area after left coronary artery liga-
tion. Masson trichrome staining of a cross-section of 
hearts on day 14 after MI showed reduced fibrosis 
in hearts injected with CD34+ progenitors (Figure 8A). 
Heart weight/body weight ratio was also decreased in 
mice receiving CD34+ progenitors (Figure 8B), indicat-
ing suppression of adverse remodeling after MI. Echo-
cardiography demonstrated significantly improved 
cardiac contractility as measured by ejection fraction 
(Figure 8C) and fractional shortening (Figure 8D) at 1 
and 2 weeks after MI in hearts receiving CD34+ pro-
genitors when compared with hearts receiving con-
trol fibroblasts. CD34+ progenitor implantation also 
improved morphological and hemodynamic indices as 
assessed by echocardiography (Table I in the online-
only Data Supplement). CD34+ cells were transduced 
with GFP before transplantation to track the fate of 
implanted cells. Immunofluorescence demonstrated 
that the implantation of CD34+ progenitors resulted 
in formation of human CD31+ blood vessels, whereas 
implantation of human fibroblasts formed none (Figure 
XIA through XIC in the online-only Data Supplement). 
We also observed that human CD31+ blood vessels 
were integrated with host mouse CD31+ vasculature 
(Figure XIB and Movie II in the online-only Data Supple-
ment).
Figure 5 Continued. course of mRNA level of SOX17 during the induction of iECs (n=4). B, Immunoblot of SOX17 in adult 
fibroblasts and iECs (C). D through F, The representative immunoblots (D) and their statistical analysis (E), and the quantitative 
PCR analysis (F) of SOX17 and EC-specific markers VE-cadherin, CD31, and FLK1 in iECs infected with lentivirus-expressing 
SOX17-shRNA or scramble shRNA (n=4). G‒I, The representative immunoblots (G) and their statistical analysis (H), and the 
quantitative PCR analysis (I) of SOX17 and EC-specific markers VE-cadherin, CD31, and FLK1 in iECs infected with retrovirus-ex-
pressing SOX17-GFP or GFP (n=4). J and K, Representative flow-cytometry overlay plots of the endothelial markers VE-cadherin 
(J) and statistical analysis (K) of percentage of VE-cadherin‒positive cells in iECs overexpressed with SOX17-GFP or GFP. Data 
are presented as mean±SE; *P<0.05, ***P<0.001, compared with day 0 in A; #P<0.05, ###P<0.001, compared with day 3 in 
A; &P<0.05 compared with day 7 in A. *P<0.05, **P<0.01, compared with control in E, F, H, and I. Using repeated measures 
1-way analysis of variance in B, the Student t test with multiple comparisons (Bonferroni Correction) in E, F, H, and I, and the 
Student t test in K.
SOX17 Regulation of Lineage Conversion
ORIGINAL RESEARCH 
ARTICLE
Circulation. 2017;135:2505–2523. DOI: 10.1161/CIRCULATIONAHA.116.025722 June 20/27, 2017 2517
Figure 6. Depletion of SOX17 facilitates the induction of erythroblasts from CD34+ progenitors.  
A, Quantitative polymerase chain reaction (PCR) analysis of SOX17 in fibroblasts, CD34+ progenitors, and induced 
Erythroblasts (iErythroblasts) at days 2 and 4 (n=3). B, The gene expression levels of hematopoietic transcription factors 
(GATA1, PU.1, RUNX) and SOX17 in iErythroblasts infected with lentivirus-expressing SOX17-1shRNA using scramble 
shRNA as control. C and D, Representative flow-cytometry overlay plots of the erythroblasts/erythrocytes markers human 
CD235a (C), and statistical analysis (D) of percentage of CD235a+ cells in iErythroblasts infected with lentivirus-express-
ing SOX17-shRNA or scramble shRNA. E and F, Representative images (E) and statistical analysis (F) of erythroid colony-
forming cell (CFC) assays in iErythroblasts infected with SOX17-shRNA or scramble shRNA. The infected cells expressed 
GFP because the pLL3.7-GFP lentivectors were applied to express SOX17-shRNA or scramble shRNA. Data are presented 
as mean±SE; *P<0.05, **P<0.01, compared with fibroblasts in A, compared with scramble shRNA in B, D, and F, using 
1-way analysis of variance in A, Student t test with multiple comparisons (Bonferroni Correction) in B, and the Student t 
test in D and F.
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Figure 7. In vivo angiogenesis of fibroblast-derived CD34+ progenitors. 
A, Representative gross images (upper) and H&E staining images of section (lower) of explanted gels at day 7 of the angiogen-
esis assay. B‒D, Representative confocal micrographs (B) of immunohistochemistry staining of human CD235a (red, left) or 
mouse TER119 (red, right) and anti-human CD31 (green) in the explanted plugs of CD34+ progenitors. Nuclei stained (Continued )  
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To further confirm the functionality of human neoves-
sels in the myocardium, fluorescence-labeled UEA I and 
GS-IB4 were intravenously injected before harvesting 
the heart. We observed that GFP colocalized with UEA 
I (Figure 8E and 8F) demonstrated that implantation of 
CD34+ progenitors formed functional human vessels in 
the myocardium after MI.
DISCUSSION
Here we demonstrate a novel approach for the re-
programming of human fibroblasts into ECs that also 
gives rise to erythroblasts by the dedifferentiation into 
intermediate CD34+ progenitors. We identified the de-
velopmental transcription factor SOX17 as a tunable 
rheostat-like switch converting CD34+ cells to both 
lineages. Implantation of human CD34+ progenitors 
in immune deficient NOD-SCID mice gave rise to hu-
man ECs capable of forming blood vessels carrying 
erythrocytes, markedly enhancing human microves-
sel generation and cardiac function after MI. Unlike 
pluripotent stem cells, fibroblasts dedifferentiated to 
CD34+ progenitors did not form any teratomas after 
implantation, thus underscoring their safety for trans-
lational applications in vascular engineering and re-
vascularization. It is important to note that systemic 
intravenous injections of human and mouse lectins 
into the recipient mice demonstrated that the neoves-
sels formed by the implanted human fibroblast-derived 
CD34+ progenitor cells are functional and communi-
cate with the host mouse vasculature.
Previous approaches to generating ECs from fibro-
blasts involved the ectopic expression of EC-specific 
transcription factors,11,12 which have relatively low 
yield and persistence of fibroblast markers, thus limit-
ing their therapeutic potential. Other approaches in-
volved dedifferentiation by Yamanaka factors without 
genetically directing cells toward the EC lineage.8–10 
In the present study, we show a third strategy involv-
ing the generation of intermediate dedifferentiated 
CD34+ progenitors and then genetically modulating 
the transcription factor SOX17 to direct lineage fate 
to iECs and iErythroblasts. Thus, in this method, the 
intermediate CD34+ progenitors can be directed to 
form both iECs and erythroid lineage cells with thera-
peutic potential. After purification for CD34+ cells us-
ing magnetic beads, not all cells expressed CD34 by 
subsequent flow-cytometric analysis, which may be 
indicative of CD34 internalization or differences in 
the specificity and sensitivity between magnetic bead 
sorting and flow-cytometry analysis.
To define transcriptional mechanisms underlying 
the generation of iECs and erythrocytes, we identified 
by transcriptomic analysis of CD34+ cells the requisite 
role of SOX17 as an essential transcription factor re-
sponsible for the conversion. SOX17, a member of the 
Sry-related high-mobility group domain family F (SoxF) 
transcriptional factor,27 is a key regulator of endothelial 
and hematopoietic developmental during embryogen-
esis.28–32 We showed that SOX17 was required for en-
dothelial lineage conversion and that its overexpression 
markedly enhanced the generation of iECs from fibro-
blasts. Further, depletion of SOX17 facilitated the gen-
eration of erythrocytes. The regulatory role of SOX17 at 
the CD34 bifurcation point thus specified the conversion 
to iEC and iErythroblast fates. This finding is reminiscent 
of the role of SOX17 during embryonic development, 
during which SOX17 regulates EC to hematopoietic fate 
switch.33 Specifically, loss of SOX17-mediated repres-
sion of hematopoietic transcription factors Runx1 and 
Gata2 prevented EC generation and augmented blood 
cell generation.33
The described method of iEC and iErythroblast gen-
eration has a distinct advantage in that it delineates for 
the first time the generation of cells capable of forming 
blood vessels and erythrocytes in vivo. We demonstrat-
ed that transplantation of CD34+ progenitors in subcu-
taneous Matrigel plugs induced formation of blood ves-
sels comprised of human ECs and perfused with human 
erythrocytes. A likely mechanism by which transplanted 
CD34+ progenitors give rise to both cells may be the re-
lease of endothelial differentiation cues in ischemic niche 
such as vascular endothelial growth factor and the pres-
ence of erythropoietin in the circulating blood,34–37 which 
in turn regulate SOX17 expression to optimize genera-
tion of both cells.
Our transcriptomic analysis of CD34+ progenitors 
and iECs indicated that iECs exhibited the gene expres-
sion profile similar to adult primary ECs, whereas CD34+ 
Figure 7 Continued. by DAPI. Scale bars, 5 µm. C and D, Quantification and statistical analysis of human vessels (CD31+) in 
the explanted plugs of CD34+ progenitors, endothelial cells (ECs), or fibroblasts (C), and the composition of vessels (CD31+) 
with human RBC (CD235a+) in the explanted plugs of CD34+ progenitors and ECs (D). N.D.indicates not detected. E through G, 
The analysis of functionality of human vessels formed by GFP-labeled CD34+ progenitors in the angiogenesis plugs. UEA I (labels 
human endothelium) and GS-IB4 (labels mouse endothelium) were intravenously injected 1 hour before explantation of plugs. 
Representative confocal images of human vessels (red) and mouse host vessels (magenta) (E), and integration of human vessels 
(red) and mouse host vessels (magenta) in the plugs implanted with human CD34+ progenitors (F). The quantification of UEA I+ 
vessels in the plugs implanted with CD34+ progenitors and ECs (G). Data are presented as mean±SE; *P<0.05, ***P<0.001, 
compared with fibroblasts in C, compared with ECs in C, D, and G, using 1-way analysis of variance in C and the Student t test 
in D and G.
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Figure 8. Regenerative potential of fibroblast-derived CD34+ progenitors after myocardial infarction (MI). 
A, Images of Masson’s trichrome staining of myocardial cross-sections 2 weeks after MI and M-mode echocardiography images 
at baseline, 1 week after MI, and 2 weeks after MI. B‒D, The statistical analysis of heart weight/body weight (B) 2 weeks after 
MI with CD34+ progenitor or fibroblast treatment, ejection fraction (C), and fraction shortening (D) at baseline (Continued )  
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progenitors retained fibroblast signatures such as col-
lagen1a and collagen3a. Gain of EC identity and con-
comitant loss of fibroblast identity occurred during the 
transition from the CD34+ progenitor to the iEC state. 
Although CD34+ progenitors exhibited residual fibroblast 
gene expression, implantation of CD34+ progenitors in 
the infarcted myocardium reduced fibrosis, suggesting 
that the imprinted fibroblast memory was lost in situ in 
the ischemic environment.
Previous studies described the role of ETV2 (ER71) 
in inducing fibroblast to endothelial conversion.11,12 
However, we did not find its significant upregulation. 
Our approach was guided by unbiased transcriptomic 
analysis of endogenous transcription factors upregu-
lated during dedifferentiation and lineage conversion. 
Although endogenous ETV2 was not upregulated dur-
ing dedifferentiation, its overexpression can direct 
fibroblasts toward EC lineage.11,12 Our results are in 
accord with an interesting lineage tracing study show-
ing that p53 signaling mediated in situ conversion 
of endogenous fibroblasts to ECs leads to improved 
cardiac function after MI,38 although these studies did 
not address whether there was an intermediate CD34+ 
progenitor cell responsible for EC conversion. Recent 
studies also show that innate immunity is a critical 
regulator for reprogramming of fibroblasts into the 
pluripotent state as well as transdifferentiating fibro-
blasts to ECs.39,40 Because MI activates inflammatory 
pathways and innate immunity, it is possible that this 
serves as a cue for implanted CD34+ cells to initiate in 
situ reprogramming to iECs and iErythroblasts.
SOX17, together with Notch1, regulates the em-
bryonic EC-hematopoietic fate transition.33,41 SOX17 
prevented hematopoietic cell fate of hemangioblasts 
and hemogenic ECs by repressing the expression of 
hematopoietic transcription factors, whereas loss of 
SOX17 instructed differentiation toward hematopoi-
etic fate.33 We did not examine the role of Notch1 in 
regulating CD34+ cell to iEC transition because our 
transcriptomic analysis showed that it did not increase 
during transdifferentiation. In addition, SOX17 was 
selectively expressed in mouse embryonic and adult 
arterial ECs, where it was required for maintaining ar-
terial identity42 and integrity43 consistent with our find-
ing of the essential importance of SOX17 in mediating 
generation of iECs. It has also been recently shown 
that SOX17 expression can enhance the maturation 
and engraftment of endothelial cells derived from am-
niotic cells.44 It is therefore possible that the SOX17 
expression in fibroblast-derived ECs similarly helped 
to mature and engraft the ECs derived from the pro-
genitors we implanted.
In addition to identifying the bilineage differentia-
tion potential of fibroblast-derived CD34+ progenitors 
and obligatory role of SOX17 in iEC and iErythroblast 
generation, we found that dedifferentiation upregu-
lated telomerase activity of iECs. This finding may 
be the result of the initial introduction of pluripotency 
factors that activated embryonic transcriptional pro-
grams. Activation of telomerase may be important 
for autologous cell therapy, which requires extensive 
in vitro cell expansion because telomeres undergo 
shortening during cell expansion.21–23 We found that 
dedifferentiation in fact upregulated telomerase in the 
CD34+ progenitors undergoing lineage conversion, 
which may induce generation of blood vessels with 
greater survival advantage in ischemic tissue. It is 
interesting to note that the dedifferentiation of adult 
ECs to vascular progenitors has also been shown to 
generate cells with significant vascularization poten-
tial,45 which may reflect some resilience to senes-
cence.
We cannot exclude the possibility that the CD34+ 
progenitor cells derived from fibroblasts contain sub-
populations of cells that may be poised to give rise only 
to endothelial or erythroid lineage cells. However, our 
flow-cytometric analysis of the CD34+ population did not 
show any evidence of endothelial or erythroid markers, 
suggesting that they are uncommitted at this stage.
In summary, our studies establish a novel role for 
the transcription factor SOX17 as a critical endog-
enous regulator of the transition from fibroblasts to 
ECs and to erythrocytes by the dedifferentiation to 
CD34+ progenitors (Figure 8G). Dedifferentiation of 
adult fibroblasts in part recapitulates embryonic de-
velopment as evidenced by the generation of progeni-
tors that can give rise to endothelial and erythroid 
cells and express telomerase. CD34+ progenitors in 
situ gave rise to functional human ECs and erythro-
cytes and displayed profound vasculogenesis and 
Figure 8 Continued. (before MI), 1 week after MI, and 2 weeks after MI with CD34+ progenitor or fibroblast  
treatment.(E, UEA I and GS-IB4 (intravenously injected 1 hour before heart explantation). Representative confocal micro-
graphs of myocardial cross-section  2 weeks after MI implanted with GFP-prelabeled human CD34+ progenitor treatment. 
Nuclei stained with DAPI (blue). Scale bars, 50 µm. F, Human vessels (UEA I+, red) were quantified per 40 mm2 visual 
field in sections of the heart that were in proximity to the injection sites 2 weeks after MI with human CD34+ progenitor 
(n=6) or fibroblast (n=4) treatment. N.D. indicates not detected. Data are presented as mean±SE; *P<0.05, **P<0.01, 
***P<0.001, compared with fibroblasts using the Student t test in B and F, and repeated measures 2-way analysis of 
variance in C and D. G, Overview of a differential role of SOX17 in the induction of endothelial cells and erythroblasts from 
CD34+ progenitors.
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restored cardiac function after transplantation, thus 
highlighting the potential therapeutic role of such pro-
genitors.
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